Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02713204 · ClinicalTrials.gov registry record · Phase 2
Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection
A Phase 2 study of Neovascular Age-related Macular Degeneration, sponsored by Regeneron Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 365
- Enrollment target
- 20
- Study locations
NCT02713204: Completed Phase 2 study of Neovascular Age-related Macular Degeneration, sponsored by Regeneron Pharmaceuticals.
NCT02713204 is a Phase 2 study of Neovascular Age-related Macular Degeneration that has completed, run by Regeneron Pharmaceuticals. The registered enrollment target is 365 participants, roughly in line with the 398-participant average among 33 other Neovascular Age-related Macular Degeneration trials with a reported enrollment target. The trial reports 20 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02713204, a Phase 2 study of Neovascular Age-related Macular Degeneration, has completed, sponsored by Regeneron Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 365 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective of the study is to compare the efficacy of intravitreal (IVT)-administered REGN910-3 compared to intravitreal aflibercept injection (IAI).
Primary Outcome
Visual function of the study eye was assessed using the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol at 4 meters. Best Corrected Visual Acuity (BCVA) score was measured using an eye chart and was reported as the number of letters read correctly at a testing distance of 4 meters using the ETDRS Scale (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of
Conditions Studied
Interventions
- DRUG REGN910-3
- DRUG Intravitreal Aflibercept Injection (IAI)
Study Locations (20)
California
- Regeneron Investigational Site - Arcadia
- Regeneron Investigational Site - Bakersfield
- Regeneron Investigational Site - Beverly Hills
- Regeneron Investigational Site - Encino
- Regeneron Investigational Site 1 - Los Angeles
- Regeneron Investigational Site 2 - Los Angeles
- Regeneron Investigational Site - Mountain View
- Regeneron Investigational Site - Oceanside
- Regeneron Investigational Site 1 - Palm Desert
- Regeneron Investigational Site 2 - Palm Desert
- Regeneron Investigational Site - Palo Alto
- Regeneron Investigational Site - Poway
- Regeneron Investigational Site - Redlands
- Regeneron Investigational Site - Sacramento
Arizona
- Regeneron Investigational Site 1 - Phoenix
- Regeneron Investigational Site 2 - Phoenix
- Regeneron Investigational Site 3 - Phoenix
- Regeneron Investigational Site 1 - Tucson
- Regeneron Investigational Site 2 - Tucson
Alabama
- Regeneron Investigational Site - Mobile
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 365 participants |
| Start Date | 2016-03-31 |
| Est. Completion | 2017-10-03 |
| Phase | Phase 2 |
What the finished NCT02713204 record still lists
NCT02713204 is an interventional study that assigns participants to a tested intervention. The registered 365 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 398-participant average among 33 other Neovascular Age-related Macular Degeneration trials with a reported enrollment target.
The record links to 1 condition, with Neovascular Age-related Macular Degeneration appearing as the primary indexed condition, and to 2 interventions - of which REGN910-3 is the first listed.
NCT02713204 names 20 study sites across 3 states, led by California, Arizona, Alabama.
Frequently Asked Questions
What is clinical trial NCT02713204 about?
NCT02713204 is a clinical study titled "Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection". The primary objective of the study is to compare the efficacy of intravitreal (IVT)-administered REGN910-3 compared to intravitreal aflibercept injection (IAI).
What is the current status of trial NCT02713204?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 365 participants. The study started on 2016-03-31. Estimated completion is 2017-10-03.
What conditions does trial NCT02713204 study?
This clinical trial studies the following conditions: Neovascular Age-related Macular Degeneration.
What interventions are being tested in trial NCT02713204?
The interventions under investigation include: REGN910-3 (DRUG), Intravitreal Aflibercept Injection (IAI) (DRUG).
Who is sponsoring clinical trial NCT02713204?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02713204 being conducted?
This trial has 20 study locations across Alabama, Arizona, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neovascular Age-related Macular Degeneration
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02713204's enrollment target sits among peer trials
365 9th of 33 higher than 25 of 33 other Neovascular Age-related Macular Degeneration trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Neovascular Age-related Macular Degeneration trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD
RECRUITING · Phase 2
-
Safety, Tolerability and PK of Subcutaneous D-4517.2 in Subjects With Wet AMD or DME
ACTIVE NOT RECRUITING · Phase 2
-
Safety and Efficacy of ADVM-022 in Treatment-Experienced Patients With Neovascular Age-related Macular Degeneration [LUNA]
ACTIVE NOT RECRUITING · Phase 2
-
Safety, Tolerability, and Efficacy Study of UBX1325 in Patients With Neovascular Age-Related Macular Degeneration (ENVISION)
COMPLETED · Phase 2
-
A Study to Assess the Efficacy and Safety of AKST4290 With Aflibercept in Patients With Newly Diagnosed nAMD
COMPLETED · Phase 2
-
Prospective OCT Study With Lucentis for Neovascular AMD (PrONTO Study)
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04049604 · 365 participants · NA
IDENTIFY Study: Natural History of Maternal Neoplasia
- NCT05065840 · 365 participants · NA
Advancing HPV Vaccination Among HIV Positive Adults: The CHAMPS Study
- NCT05303519 · 365 participants · Phase 3
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
- NCT05592626 · 365 participants · Phase 1
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI